FDA Law Blog

JANUARY 6, 2022

Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. In particular, the employee exemption, relevant to the S&G Labs Haw., S&G Labs Haw., 18 U.S.C. §

Lab Testing 52

Lab Testing Referral Individual Patient-Centered 52

FDA Law Blog

JANUARY 6, 2022

Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. In particular, the employee exemption, relevant to the S&G Labs Haw., S&G Labs Haw., 18 U.S.C. §

Lab Testing 40

Lab Testing Individual Referral Patient-Centered 40

GeriPal

FEBRUARY 6, 2025

We now have biomarkers that can reasonably approximate the degree of amyloid build-up in the brain with a simple blood test. We have two new FDA-approved medications that reduce that amyloid buildup and modestly slow down the progression of the disease. I just had lab tests done. Nate, welcome back to the GeriPal Podcast.

Primary Care 96

Primary Care Diagnosis Screening IT 96

GeriPal

SEPTEMBER 7, 2023

William: So ASCO decided to make a high priority this year to redo the guidelines, which were originally released in 2018. But I think if I were under normal constraints of the healthcare system, I wouldn’t have that time. He had a very aggressive lymphoma, highly aggressive, with a lot of different medical conditions.

Patient-Centered 129

Patient-Centered IT Patients Clinic 129